Search the Newsreel

Canaccord raises Artivion stock price target on acquisition, PMA approval

Canaccord raised its price target for Artivion Inc. (NYSE:AORT) to $39 from $36, maintaining a Buy rating, following the company's acquisition of Endospan and PMA approval for AMDS. Artivion's second-quarter revenue of $125.8 million and adjusted EBITDA of $26.4 million both surpassed analyst estimates, …

Viomi Technology Co Ltd (VIOT) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Viomi Technology Co Ltd (VIOT), noting that no earnings forecast score is currently available, contrasting with the Household Goods industry's average of 7.03. Analysts have set an average price target of $5.00 for VIOT, indicating a significant …

RA Capital reports 10.67M-share Inovio (NASDAQ: INO) stake capped at 9.99%

RA Capital Management and its affiliates, including Peter Kolchinsky and Rajeev Shah, have reported a beneficial ownership of 10,666,523 shares of Inovio Pharmaceuticals, Inc. (NASDAQ: INO), which represents 9.99% of the company's common stock. This ownership includes 7,220,384 direct shares and warrants exercisable for …

red violet estimates $108.6M for working capital, acquisitions

Red Violet, Inc. (NASDAQ: RDVT) has successfully closed its underwritten public offering, raising estimated net proceeds of $108.6 million. The company plans to utilize these funds for working capital, general corporate purposes, and potential strategic acquisitions, enhancing its financial flexibility. The offering included the …

Long-Term Growth Opportunities Remain for Artivion (AORT) Despite Challenges

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 …

Navios Maritime Partners (0Q5A) Q4 2025 Earnings Report - Results, Call & Slides

Navios Maritime Partners (0Q5A) reported its Q4 2025 earnings, surpassing analyst expectations. The company achieved an actual EPS of $3.40 against a consensus of $2.38, and actual revenue of $365.55M, beating the expected $330.65M, representing a 9.93% year-over-year revenue growth. The next earnings report …

red violet Announces Closing of $115 Million Underwritten

Red Violet, Inc. (NASDAQ: RDVT) announced the closing of its underwritten public offering of 1,916,667 shares of common stock, including the full exercise of the underwriters' option, totaling $115 million. The company estimates net proceeds of approximately $108.6 million and plans to use these …

Navios Maritime Partners Number of Employees 2026 | Employee Count & Headcount Data

Navios Maritime Partners LP (NMM) has a global workforce of 658 employees as of March 2026, marking a 29.0% growth from 2023. The company, headquartered in Dimos Piraeus, Greece, is not actively hiring despite its workforce growth, and its employees are primarily concentrated in …

Artivion Q2 Earnings Call Highlights

Key Points Interested in Artivion, Inc.? Here are five stocks we like better. Artivion's Q2 revenue rose 9% to $125.8 million on a constant-currency basis, driven by 12% growth in stent grafts and 18% growth in On-X valves. Adjusted EBITDA increased 7% to $26.4 …

Earnings call transcript: Supernus and Indivior post Q2 2026 beat on merger news

Supernus Pharmaceuticals and Indivior Pharmaceuticals announced a Q2 2026 earnings beat and their planned all-stock merger. The combined entity will focus on central nervous system drugs, aiming for $2.2 billion in annual revenue and $125 million in annual cost savings. The merger, expected to …

Artivion, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:AORT) 2026-08-07

Artivion, Inc. (AORT) released its 2026 Q2 earnings call presentation. The company reported an EPS of $0.13, beating estimates by $0.03, and revenue of $125.76 million, an 11.32% year-over-year increase, beating estimates by $5.74 million. This article provides access to the slide deck published …

HC Wainwright Predicts Indivior's Q3 Earnings (NASDAQ:INDV)

HC Wainwright has increased its Q3 2026 EPS estimates for Indivior (NASDAQ:INDV) to $0.93 from $0.78, with forecasts rising through FY2030. Despite a recent price target cut by Barclays, analyst sentiment remains a "Moderate Buy" with an average target of $45.17. Indivior's shares opened …

Is Artivion Inc (AORT) Undervalued Despite $125.8 Million Revenue in Q2? GF Score: 82/100

Artivion Inc (AORT) reported Q2 2026 revenues of $125.8 million, an 11% year-over-year increase, exceeding analyst estimates, yet posted a net loss of $13.5 million. Despite the loss, driven partly by foreign currency revaluation and increased operating expenses, the company strengthened its product portfolio …

Earnings call transcript: Artivion tops Q2 2026 revenue forecast as shares rise

Inovio Pharmaceuticals (INO.US) will release its earnings report after market close on August 12.

Inovio Pharmaceuticals (INO.US) is scheduled to release its earnings report after the market closes on August 12. This announcement provides investors and analysts with a specific date to anticipate the company's financial performance update.

Earnings Flash (AORT) Artivion, Inc. Posts Q2 Adjusted EPS $0.13 per Share, Vs. FactSet Est of $0.10

Artivion, Inc. (AORT) announced its Q2 adjusted EPS of $0.13 per share, surpassing the FactSet estimate of $0.10. This indicates a stronger financial performance than anticipated by analysts.

Artivion (AORT) Q2 Earnings Meet Estimates

Artivion (AORT) reported Q2 earnings of $0.13 per share, meeting the Zacks Consensus Estimate, though this is down from $0.24 a year ago. The company's revenues for the quarter were $125.76 million, surpassing estimates by 4.02%. Artivion's stock has underperformed the S&P 500 this …

Artivion Q2 2026 slides: FDA wins fuel aortic arch expansion

Artivion Inc. reported strong Q2 2026 results, with 9% constant-currency revenue growth driven by stent grafts and On-X mechanical heart valves. The company achieved two major regulatory milestones: FDA PMA approval for the AMDS Hybrid Prosthesis and the completion of the Endospan acquisition following …

Artivion (NYSE:AORT) Delivers Strong Q2 CY2026 Numbers

Artivion (NYSE:AORT) reported strong Q2 CY2026 results, with revenue of $125.8 million, beating analyst estimates by 4.4%, and non-GAAP EPS of $0.13, exceeding estimates by 34.5%. The medical device company reconfirmed its full-year revenue guidance and provided optimistic EBITDA guidance. Despite a decrease in …

Artivion: Q2 Earnings Snapshot

Artivion, Inc. (AORT) reported a second-quarter loss of $13.5 million, or 28 cents per share, which contrasts with a profit in the same period last year. Adjusted earnings for the biological medical device maker were 13 cents per share, with revenue reaching $130.8 million. …

Earnings Flash (AORT) Artivion, Inc. Reports Q2 Revenue $125.8M, vs. FactSet Est of $120.0M

Artivion, Inc. (AORT) has reported its Q2 revenue of $125.8 million, surpassing FactSet's estimate of $120.0 million. This earnings flash indicates a positive financial performance for the medical device company. The news was published on August 6, 2026, at 05:07 pm EDT.

Artivion Reports Second Quarter 2026 Financial Results

Artivion, Inc. announced strong financial results for the second quarter of 2026, with revenue increasing 11% on a GAAP basis and 9% on a constant currency basis. The company reported adjusted EBITDA growth of 7% and highlighted key achievements including the acquisition of Endospan …

AUMOVIO SE: Vorstand Ismail Dagli kauft Aktien über XETRA zu 35,95 EUR

AUMOVIO SE: Vorstandskauf von 108.780 Aktien zu 38,85 Euro je Aktie

Artivion earnings on deck: Can FDA approval revive growth? By Investing.com

Artivion Inc. is set to report its second-quarter earnings, with investors focusing on whether its recent FDA premarket approval for the AMDS Hybrid Prosthesis can counteract slowing sales and revive growth. Despite a 46% drop in shares from their 52-week high and a sequential …

FMR LLC, Abigail Johnson report 4.0% Artivion Inc (AORT) ownership in 13G/A

FMR LLC and Abigail P. Johnson have filed a Schedule 13G/A, reporting a 4.0% beneficial ownership stake in Artivion Inc (AORT). As of June 30, 2026, they collectively beneficially own 1,963,471.40 shares, with FMR LLC holding sole voting power over 1,962,433.00 shares and sole …

FMR LLC (INO) discloses 8.45M Inovio shares, including major fund holder

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 8,454,797 shares of Inovio Pharmaceuticals (INO) common stock, representing a 10.3% stake, as of June 30, 2026. This includes Fidelity Small Cap Growth Fund holding 5,632,660 shares, or 6.8% of the outstanding common …

Earnings Call: Aumovio senkt Prognose für 2026 nach schwachem Umsatz im zweiten Quartal

Artivion (AORT) Earnings Date and Reports 2026 $AORT

Cheviot Company approves ₹25 dividend, reappoints Utkarsh Kanoria at AGM

Aumovio bestätigt Prognose und warnt vor anhaltend schwierigen Bedingungen im Automarkt

Red Violet Offering Expected to Close Aug. 7 >RDVT

Red Violet, Inc. (RDVT) announced that its previously priced underwritten public offering of common stock is expected to close on August 7, 2026. The offering is contingent upon customary closing conditions.

Red Violet prices $100 million public stock offering at $60 By Investing.com

Red Violet Inc. (NASDAQ:RDVT) has priced an underwritten public offering of 1,666,667 shares of common stock at $60.00 per share, aiming to raise $100 million in gross proceeds. The company plans to use the net proceeds for working capital, general corporate purposes, and potential …

Red Violet prices $100M public offering of comm...

Red Violet, Inc. has announced the pricing of an underwritten public offering of 1,666,667 shares of common stock at $60 per share, aiming to raise $100 million before fees. The offering is expected to close on August 7, 2026, with an option for underwriters …

How AMDS Launch Momentum and Capital Discipline Could Reframe Artivion’s (AORT) Growth-Risk Balance

Artivion (AORT), formerly CryoLife, is gaining attention due to the positive physician feedback and early clinical uptake of its AMDS aortic device in the U.S. This new product and focus on capital efficiency could significantly impact the company's growth and operational strategy. The article …

Red Violet announces public offering of common stock

Red Violet Inc. (NASDAQ:RDVT) has announced a proposed underwritten public offering of its common stock. The company plans to use the net proceeds for working capital, general corporate purposes, and potential strategic acquisitions. Raymond James and Needham & Company are serving as joint book-running …